**Core Concept:** Anti-diabetic drugs broadly fall into three categories: insulin secretagogues, insulin sensitizers, and glucagon-like peptide-1 (GLP-1) agonists. Weight gain is a known side effect of certain anti-diabetic medications.

**Why the Correct Answer is Right:** Metformin, a biguanide, is an insulin sensitizer, which lowers blood glucose levels by decreasing hepatic glucose production and increasing insulin sensitivity in muscle cells. It does not cause significant weight gain.

**Why Each Wrong Option is Incorrect:**

A. **Gliclazide** is a sulfonylurea, which facilitates insulin secretion from pancreatic beta cells. While it helps in lowering blood glucose, it is not associated with significant weight gain.

B. **Rosiglitazone** is a thiazolidinedione, a PPAR-gamma agonist, which increases insulin sensitivity in adipose tissue, muscle, and liver. Weight gain is a known side effect of this drug.

C. **Sitagliptin** is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretins (GLP-1 and GIP) thereby promoting insulin secretion and reducing glucagon secretion. Sitagliptin may cause weight gain in certain patients.

D. **Albiglutide** is a glucagon-like peptide-1 (GLP-1) receptor agonist, which increases insulin secretion, reduces glucagon secretion, and slows gastric emptying, leading to improved glucose control and weight gain in some patients.

**Clinical Pearl:** Weight gain is a common concern when prescribing anti-diabetic medications to patients, especially those who are already overweight or obese. It is essential to weigh the benefits against the potential risks when choosing a treatment option for patients with diabetes.